choriogonadotropin alfa (Rx)

Brand and Other Names:Ovidrel, Novarel, more...Pregnyl, chorionic gonadotropin
  • Print

Dosing & Uses


Dosage Forms & Strengths

prefilled syringe

  • 250mcg

powder for reconstitution

  • 10,000 units/vial

Induction of Ovulation & Pregnancy

Ovidrel: 250 mcg SC one day following last dose of follicle stimulating agent; use only after adequate follicular development has been determined; hold treatment if there is excessive ovarian response

Novarel, Pregnyl, Generics: 5,000-10,000 units 1 day following last dose of menotropins

Induction of Spermatogenesis

Novarel, Pregnyl, Generics

  • Hypogonadotropic and hypogonadism in males: 1000-2000 units 2-3 times/week (may require 2-3 months of therapy); if needed, add follitropin alfa or menopausal gonadotropin to induce spermatogenesis; continue hCG therapy at dose required to maintain testosterone levels

Other Indications & Uses

Novarel: Induction of ovulation & pregnancy in infertile women with secondary anovulation who have been appropriately pretreated with menotropins/FSH

Ovidrel: Induction of final follicular maturation & early luteinization in infertile women who have undergone pituitary desensitization & who have been appropriately retreated with follicle stimulating hormones

Novarel, Pregnyl

  • Prepubertal cryptorchidism not due to anatomical obstruction
  • Selected cases of male secondary hypogonadotropic hypogonadism

Dosage Forms & Strengths

prefilled syringe

  • 250mcg

powder for injection

  • 10,000 units

Prepubertal Cryptorchidism Not Caused By Anatomical Obstruction

Novarel, Pregnyl

  • May institute therapy between ages of 4 and 9
  • 4,000 units IM 3 times/week for 3 weeks
  • 5,000 units IM every second day for 4 injections
  • 15 injections of 500 to 1,000 units IM over a period of 6 weeks
  • 500 units IM 3 times/week for 4-6 weeks; if course of treatment not successful, begin another 1 month later, giving 1,000 units/injection

Male Hypogonadotropic Hypogonadism

Novarel, Pregnyl

  • 500-1,000 units IM 3 times/week for 3 weeks, followed by same dose twice/week for 3 weeks
  • 4,000 units IM 3 times/week for 6-9 months; following that dosage may be reduced to 2,000 units 3 times/week for an additional 3 months

Adverse Effects



  • Ovarian cyst (3%)
  • Ovarian hyperstimulation (2-3%)
  • Abdominal pain (3-4%)
  • Nausea (3%)
  • Vomiting (3%)
  • Injection site inflammation (<2%)



  • Breast pain
  • Cervical lesion
  • Cough
  • Albuminuria
  • Back pain
  • Breast pain
  • Cardiac arrhythmia
  • Dizziness
  • Emotional lability
  • Genial herpes
  • Hyperglycemia
  • Pruritus
  • Urinary tract infection
  • Vaginal hemorrhage
  • Vaginitis

Frequency Not Defined

Novarel, Pregnyl

  • Headache
  • Irritability
  • Depression
  • Edema
  • Restlessness
  • Gynecomastia
  • Precocious puberty
  • Fatigue
  • Arterial thrombus
  • Ovarian hyperstimulation syndrome
  • Overian cyst rupture




  • Hypersensitivity to component
  • Primary ovarian failure
  • Uncontrolled thyroid or adrenal dysfunction
  • Uncontrolled organic intracranial lesion such as pituitary tumor
  • Undiagnosed abnormal uterine bleeding
  • Ovarian cyst or enlargement of undetermined origin
  • Sex hormone dependent tumor of reproductive tract and accessory organs
  • Pregnancy

Novarel, Pregnyl

  • Hypersensitivity to drug or components
  • Precocious puberty
  • Prostatic carcinoma or other androgen-dependent neoplasm


Administer only after assessing adequate follicular development by serum estradiol & vaginal ultrasonography


  • Withhold where clinically significant ovarian enlargement or excessive estradiol production to reduce risk of ovarian hyperstimulation syndrome
  • Ovarian hyperstimulation syndrome is characterized by mild to moderate ovarian enlargement may occur, accompanied by abdominal distension and/or abdominal pain; usually regresses without treatment in 2-3 wk; may progress rapidly to a serious medical event characterized by dramatic increase in vascular permeability, which may result in rapid fluid accumulation in peritoneal cavity, thorax and/or pericardium
  • Risk of multiple births
  • Potential for arterial thromboembolism
  • Risk of enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum

Novarel, Pregnyl

  • Use with caution in cardiovascular disease, asthma, history of migraines, renal impairment, seizure disorders
  • Not effective in treatment of obesity
  • May induce precocious puberty in children being treated for cryptorchidism (discontinue if signs of precocious puberty occur
  • Safety and efficacy not established in children <4 years of age

Pregnancy & Lactation

Pregnancy Category: X

Lactation: Not known if distributed in breast milk; use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.



Mechanism of Action


  • Produced by recombinant DNA techniques: human chorionic gonadotropin; stimulates late follicular maturation & resumption of oocyte meiosis & initiates rupture of pre-ovulatory ovarian follicle

Novarel, Pregnyl

  • Obtained from the urine of pregnant women; stimulates production of gonadal steroid hornones by causing production of androgen by the testes
  • Stimulates ovulation by acting as a substitute for luteinizing hormone



  • Vd: 21.4 L
  • Time to peak: 12-24 hr
  • Bioavailability: 40%
  • Half-life: 4 hr
  • Time to peak: 12-24 hr
  • Excretion: Urine (10%)

Novarel, Pregnyl

  • Half-life: 11 hr intial; 23 hr terminal
  • Excretion: Urine


Ovidrel subcutaneous
250 mcg/0.5 mL solution

Copyright © 2010 First DataBank, Inc.


Patient Handout

Patient Education
choriogonadotropin alfa,human recombinant subcutaneous


(KOR-ee-o-goe-nad-oh-troe-pin AL-fa)


USES: This medication is used as part of a treatment program for certain fertility problems in women. It is generally used in combination with another hormone (FSH). This medication provides the hormone (hCG), which stimulates the release of a mature egg (ovulation) and helps you become pregnant.This medication is not recommended for women whose ovaries no longer make eggs properly (primary ovarian failure).This medication has not been shown to be effective for weight loss and should not be used for this purpose due to risk of serious side effects.

HOW TO USE: Read the Patient Information Leaflet before starting this medication and each time you get a refill of this medication because new information may be available. You will be trained by a healthcare professional on how to properly use this medication. If any of the information is unclear, consult your healthcare professional.Inject this medication under the skin (subcutaneously) usually one day after your last dose of the hormone FSH, or as directed by your doctor. Follow your doctor's instruction closely to ensure proper timing of this medication.Wash hands with soap and water before using this medication. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid.Before injecting each dose, clean the injection site with rubbing alcohol. Inject the prescribed dose as directed by your doctor. Discard any unused portion of the medication immediately after the injection. Do not save it for future use. Do not change the dose unless instructed by your doctor or use this medication for a longer period than prescribed.Learn how to store and discard syringes, needles, and medical supplies safely. Consult your pharmacist for more information.

SIDE EFFECTS: Redness or pain at the injection site, mild abdominal pain, mood changes, or mild nausea/vomiting may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if the following unlikely but very serious side effect occurs: unusual vaginal bleeding.Seek immediate medical attention if any of these rare but very serious side effects occur: weakness on one side of the body, trouble speaking, vision changes, sudden/severe headache, pain/swelling of the calf muscles, chest pain, shortness of breath, swelling of ankles/hands/feet.This medication may cause a condition known as Ovarian Hyperstimulation Syndrome (OHSS). This condition may occur during therapy and after treatment has been discontinued. Rarely, serious OHSS causes fluid to suddenly build up in the stomach, chest, and heart area. Seek immediate medical attention if you develop the following side effects: severe pain or swelling in the lower abdominal (pelvic) area, severe nausea/vomiting, sudden/rapid weight gain, decreased urination.A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Before using this medication, tell your doctor or pharmacist if you are allergic to it; or to other products containing chorionic gonadotropin (hCG); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: other fertility problems (e.g., primary ovarian failure), thyroid or adrenal gland problems, cancer of the reproductive organs (e.g., breast, uterus, ovary), tumor in the brain (e.g., pituitary tumor), abnormal uterine/vaginal bleeding, unexplained ovarian cysts or enlarged ovaries.Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood clots, stroke, certain heart diseases (e.g., heart attacks), liver disease, lung problems (e.g., asthma).Multiple births may occur because of this treatment. Consult your doctor for more details.Stop using this medication when you become pregnant. This medication must not be used during pregnancy. If you think you may be pregnant, tell your doctor right away.It is not known whether this drug passes into breast milk. Consult your doctor before breast-feeding.

DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.A product that may interact with this drug is: gonadorelin.This medication may affect the results of certain lab tests (gonadotropin levels). Be sure to tell your doctor or laboratory personnel that you are taking this medication.

OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.Laboratory and/or medical tests (e.g., blood hormone tests such as estradiol levels, vaginal ultrasound) should be performed to monitor your progress and check for side effects. Consult your doctor for more details.It is important to keep all regular medical and laboratory appointments so your doctor can closely monitor your response to help reduce the risk of serious side effects and determine the timing of this medication.

MISSED DOSE: It is important to use this medication at the scheduled time. If you miss a dose and forget to use your medication, contact your doctor or pharmacist right away for instructions. Do not double the dose to catch up.

STORAGE: Store in the refrigerator. Protect from light. Do not freeze. If necessary, the prefilled syringe may be stored at room temperature for up to 30 days. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.



FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient



The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient



The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.